References
- Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005;19:105-23
- Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract 2003;9:93-110
- Kajihara M, Montagnese S, Khanna P, et al. Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases. Eur J Gastroenterol Hepatol 2010;22:628-31
- Moulignier A, Allo S, Zittoun R, Gout O. Recombinant interferon-alpha-induced chorea and frontal subcortical dementia. Neurology 2002;58:328-30
- Sunami M, Nishikawa T, Yorogi A, Shimoda M. Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha. Clin Neuropharmacol 2000;23:59-61
- Atasoy N, Ustundang Y, Konuk N, Atik L. Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection. Clin Neuropharmacol 2004;27:105-7
- Schwartz M, Hocherman S. Antipsychotic-induced rabbit syndrome: epidemiology, management and pathophysiology. CNS Drugs 2004;18:213-20
- Shuto H, Kataoka Y, Horikawa T, et al. Repeated interferonalpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997;747:348-51
- Levin T, Heresco-Levy U. Risperidone-induced rabbit syndrome: an unusual movement disorder caused by an atypical antipsychotic. Eur Neuropsychopharmacol 1999;9:137-9